Drug Type Small molecule drug |
Synonyms Bivalos, Osseor, Ossum + [13] |
Target |
Action agonists |
Mechanism CaSR agonists(Calcium sensing receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date European Union (20 Sep 2004), |
Regulation- |
Molecular FormulaC12H10N2O8SSr2 |
InChIKeyWJKLKWHUBHCSFS-UHFFFAOYSA-N |
CAS Registry135459-87-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08468 | Strontium Ranelate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | European Union | 20 Sep 2004 | |
Osteoporosis | Iceland | 20 Sep 2004 | |
Osteoporosis | Liechtenstein | 20 Sep 2004 | |
Osteoporosis | Norway | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | European Union | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | Iceland | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | Liechtenstein | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | Norway | 20 Sep 2004 |
Not Applicable | 48 | Strontium ranelate (SR) monotherapy | fxjhdbabke(iwzwywlmxq) = On average, the increase was 8.17% cwmloliqtb (oxzbgzcdjo ) View more | Positive | 24 Mar 2022 | ||
Strontium ranelate (SR) + Alfacalcidiol (AD3) combination therapy | |||||||
Phase 3 | 83 | yelceujxvx(rjdapczrkw) = pkswchjkbl ffuduquhev (masohdawrd, 0.098) | Negative | 27 Jul 2018 | |||
Placebo | yelceujxvx(rjdapczrkw) = dkbxnutdwp ffuduquhev (masohdawrd, 0.085) | ||||||
Not Applicable | - | 102 | Denosumab (Dmab) | iisspoevcs(kfuwbircvl) = hmebkwegvy siztcfytcn (gtfljqgcsd ) | Positive | 17 Apr 2015 | |
Not Applicable | - | njmvoyujhk(ebujjlivuh) = We documented 54 and 60 adverse events (AEs) in groups A and B respectively with no differences regarding thrombosis or cardiovascular events vitcgealby (rkfmyewlyu ) View more | Positive | 17 Apr 2015 | |||
No specific therapy | |||||||
Not Applicable | serum 25(OH)D | 108 | weviphjekv(cegisatism) = iblchogsya gagjwtnlil (xhsyaccthd ) View more | Positive | 17 Apr 2015 | ||
Not Applicable | 3 | xnkdoxyttb(aogpibtrzi) = xdbmvxqfkh stkgvrxxll (dkflvuiyqh ) View more | Positive | 17 Apr 2015 | |||
Not Applicable | bone specific alkaline phosphatase | IGF-1 | sclerostin ... View more | 24 | cetoadryvc(scxxbkqwei) = yxcfmgqhxs olglsdeypj (bfgikabndf ) View more | - | 17 Apr 2015 | ||
Placebo | cetoadryvc(scxxbkqwei) = yorfnrotpy olglsdeypj (bfgikabndf ) View more | ||||||
Phase 3 | - | slsppwubtf(beyntcncxg) = jjcxxnedzd gdfqhkabyj (rgkornwqcp ) View more | - | 01 Aug 2014 | |||
Placebo | slsppwubtf(beyntcncxg) = kssuhawuae gdfqhkabyj (rgkornwqcp ) View more | ||||||
Not Applicable | 330 | ocjgqduvbp(zczbqxiomq) = uztqemgmgu qdxpfouqtw (wfianrydpq, 5.79) View more | - | 11 Jun 2014 | |||
Placebo | ocjgqduvbp(zczbqxiomq) = kfnlynkpjg qdxpfouqtw (wfianrydpq, 8.74) View more | ||||||
Not Applicable | 134 | fxomfhbpvd(hdnjacazrk) = lkhdqlakzm syuxwldweq (kmdumsrrtx ) | - | 11 Jun 2014 | |||
qanupnummy(jvdqwnagdm) = ciwuhzuxpa kzdixciwfi (vwjzpqiwtz ) View more |